BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lewandowski RJ, Mulcahy MF, Kulik LM, Riaz A, Ryu RK, Baker TB, Ibrahim SM, Abecassis MI, Miller FH, Sato KT, Senthilnathan S, Resnick SA, Wang E, Gupta R, Chen R, Newman SB, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Omary RA, Benson AB 3rd, Salem R. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 2010;255:955-65. [PMID: 20501733 DOI: 10.1148/radiol.10091473] [Cited by in Crossref: 108] [Cited by in F6Publishing: 101] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Gaba RC. Chemoembolization Practice Patterns and Technical Methods Among Interventional Radiologists: Results of an Online Survey. American Journal of Roentgenology 2012;198:692-9. [DOI: 10.2214/ajr.11.7066] [Cited by in Crossref: 50] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
2 Andersen KJ, Grønbæk H, Villadsen GE, Knudsen AR, Ott P, Vildstrup H, Nielsen DT, Bharadwaz A. Chemoembolization of intermediate stage hepatocellular carcinomas: Results from a Nordic tertiary liver cancer center. Indian J Gastroenterol 2014;33:322-9. [DOI: 10.1007/s12664-013-0428-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
3 Park BV, Gaba RC, Huang YH, Chen YF, Guzman G, Lokken RP. Histology of Hepatocellular Carcinoma: Association with Clinical Features, Radiological Findings, and Locoregional Therapy Outcomes. J Clin Imaging Sci 2019;9:52. [PMID: 31819829 DOI: 10.25259/JCIS_111_2019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kennedy AS, Sangro B. Nonsurgical treatment for localized hepatocellular carcinoma. Curr Oncol Rep. 2014;16:373. [PMID: 24488546 DOI: 10.1007/s11912-013-0373-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
5 Ibrahim SM, Kulik L, Baker T, Ryu RK, Mulcahy MF, Abecassis M, Salem R, Lewandowski RJ. Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization. Cardiovasc Intervent Radiol. 2012;35:1094-1101. [PMID: 22069121 DOI: 10.1007/s00270-011-0292-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
6 Riaz A, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora R, Kulik L, Desai K, Thornburg B, Mouli S, Hickey R, Miller FH, Yaghmai V, Ganger D, Lewandowski RJ, Salem R. Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses: Riaz et al. Hepatology 2018;67:873-83. [DOI: 10.1002/hep.29480] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
7 Mahnken AH. (90)Y-glass microspheres for hepatic neoplasia. Future Oncol 2015;11:1343-54. [PMID: 25952780 DOI: 10.2217/fon.15.12] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 McDevitt JL, Mouli SK, Tyler PD, Li W, Nicolai J, Procissi D, Ragin AB, Wang YA, Lewandowski RJ, Salem R, Larson AC, Omary RA. MR imaging enables measurement of therapeutic nanoparticle uptake in rat N1-S1 liver tumors after nanoablation. J Vasc Interv Radiol 2014;25:1288-94. [PMID: 24854392 DOI: 10.1016/j.jvir.2014.03.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Somma F, D'Angelo R, Serra N, Gatta G, Grassi R, Fiore F. Use of Ethanol in the Trans-Arterial Lipiodol Embolization (TAELE) of Intermediated-Stage HCC: Is This Safer than Conventional Trans-Arterial Chemo-Embolization (c-TACE)? PLoS One 2015;10:e0129573. [PMID: 26110810 DOI: 10.1371/journal.pone.0129573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
10 Gaba RC, Lokken RP, Hickey RM, Lipnik AJ, Lewandowski RJ, Salem R, Brown DB, Walker TG, Silberzweig JE, Baerlocher MO, Echenique AM, Midia M, Mitchell JW, Padia SA, Ganguli S, Ward TJ, Weinstein JL, Nikolic B, Dariushnia SR; Society of Interventional Radiology Standards of Practice Committee. Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. J Vasc Interv Radiol 2017;28:1210-1223.e3. [PMID: 28669744 DOI: 10.1016/j.jvir.2017.04.025] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
11 Guo JH, Zhu X, Li XT, Yang RJ. Impact of serum vascular endothelial growth factor on prognosis in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. Chin J Cancer Res 2012;24:36-43. [PMID: 23359473 DOI: 10.1007/s11670-012-0036-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
12 Prajapati HJ, Dhanasekaran R, El-Rayes BF, Kauh JS, Maithel SK, Chen Z, Kim HS. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. J Vasc Interv Radiol. 2013;24:307-315. [PMID: 23375519 DOI: 10.1016/j.jvir.2012.11.026] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 5.4] [Reference Citation Analysis]
13 Wu J, Bai W, Han G, Fan D. ART score for retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma: Is it really applicable? Journal of Hepatology 2014;61:176-7. [DOI: 10.1016/j.jhep.2014.02.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Wells D, Alisky J, Ray CE Jr. Mental status changes postchemoembolization: the role of inflammatory response. Semin Intervent Radiol 2013;30:219-22. [PMID: 24436540 DOI: 10.1055/s-0033-1342965] [Reference Citation Analysis]
15 Liu K, Min XL, Peng J, Yang K, Yang L, Zhang XM. The Changes of HIF-1α and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma. J Clin Med Res 2016;8:297-302. [PMID: 26985249 DOI: 10.14740/jocmr2496w] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
16 Sangro B. Chemoembolization and radioembolization. Best Practice & Research Clinical Gastroenterology 2014;28:909-19. [DOI: 10.1016/j.bpg.2014.08.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
17 Bonekamp S, Halappa VG, Geschwind JF, Li Z, Corona-Villalobos CP, Reyes D, Bhagat N, Cosgrove DP, Pawlik TM, Mezey E. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy. Radiology. 2013;268:431-439. [PMID: 23616632 DOI: 10.1148/radiol.13121637] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
18 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol 2015;7:738-52. [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738] [Reference Citation Analysis]
19 Salem R, Lewandowski RJ. Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013;11:604-11; quiz e43-44. [PMID: 23357493 DOI: 10.1016/j.cgh.2012.12.039] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
20 Chai NX, Chapiro J. Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice. Semin Intervent Radiol 2020;37:456-65. [PMID: 33328701 DOI: 10.1055/s-0040-1719186] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Schicho A, Hellerbrand C, Krüger K, Beyer LP, Wohlgemuth W, Niessen C, Hohenstein E, Stroszczynski C, Pereira PL, Wiggermann P. Impact of Different Embolic Agents for Transarterial Chemoembolization (TACE) Procedures on Systemic Vascular Endothelial Growth Factor (VEGF) Levels. J Clin Transl Hepatol 2016;4:288-92. [PMID: 28097096 DOI: 10.14218/JCTH.2016.00058] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
22 Takayasu K. Superselective transarterial chemoembolization for hepatocellular carcinoma: recent progression and perspective. Oncology 2011;81 Suppl 1:105-10. [PMID: 22212943 DOI: 10.1159/000333269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
23 Sourianarayanane A, El-Gazzaz G, Sanabria JR, Menon KV, Quintini C, Hashimoto K, Kelly D, Eghtesad B, Miller C, Fung J, Aucejo F. Loco-regional therapy in patients with Milan Criteria-compliant hepatocellular carcinoma and short waitlist time to transplant: An outcome analysis. HPB (Oxford). 2012;14:325-332. [PMID: 22487070 DOI: 10.1111/j.1477-2574.2012.00453.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
24 Sheth RA, Hesketh R, Kong DS, Wicky S, Oklu R. Barriers to drug delivery in interventional oncology. J Vasc Interv Radiol 2013;24:1201-7. [PMID: 23735316 DOI: 10.1016/j.jvir.2013.03.034] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
25 Kamran AU, Liu Y, Li FE, Liu S, Wu JL, Zhang YW. Transcatheter Arterial Chemoembolization With Gelatin Sponge Microparticles Treated for BCLC Stage B Hepatocellular Carcinoma: A Single Center Retrospective Study. Medicine (Baltimore) 2015;94:e2154. [PMID: 26717358 DOI: 10.1097/MD.0000000000002154] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
26 Johnson P, Cawich S, Roberts P, Shah S, Gardner M, Gordon-strachan G, Pearce N. Variants of hepatic arterial supply in a Caribbean population: A computed tomography based study. Clinical Radiology 2013;68:823-7. [DOI: 10.1016/j.crad.2013.03.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
27 Ray CE Jr, Brown AC, Green TJ, Winston H, Curran C, Kreidler SM, Glueck DH, Rochon PJ. Survival outcomes in patients with advanced hepatocellular carcinoma treated with drug-eluting bead chemoembolization. AJR Am J Roentgenol 2015;204:440-7. [PMID: 25615768 DOI: 10.2214/AJR.14.12844] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
28 Apisarnthanarax S, Barry A, Cao M, Czito B, DeMatteo R, Drinane M, Hallemeier CL, Koay EJ, Lasley F, Meyer J, Owen D, Pursley J, Schaub SK, Smith G, Venepalli NK, Zibari G, Cardenes H. External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol 2021:S1879-8500(21)00233-2. [PMID: 34688956 DOI: 10.1016/j.prro.2021.09.004] [Reference Citation Analysis]
29 Seidensticker M, Streit S, Nass N, Wybranski C, Jürgens J, Brauner J, Schulz N, Kalinski T, Seidensticker R, Garlipp B, Steffen I, Ricke J, Dudeck O. Modified transarterial chemoembolization with locoregional administration of sorafenib for treating hepatocellular carcinoma: feasibility, efficacy, and safety in the VX-2 rabbit liver tumor model. Diagn Interv Radiol 2016;22:378-84. [PMID: 27328720 DOI: 10.5152/dir.2016.15462] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
30 Sangro B, Iñarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. Journal of Hepatology 2012;56:464-73. [DOI: 10.1016/j.jhep.2011.07.012] [Cited by in Crossref: 173] [Cited by in F6Publishing: 175] [Article Influence: 17.3] [Reference Citation Analysis]
31 Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology 2013;58:2188-97. [PMID: 23512791 DOI: 10.1002/hep.26382] [Cited by in Crossref: 109] [Cited by in F6Publishing: 110] [Article Influence: 12.1] [Reference Citation Analysis]
32 Dhand S, Gupta R. Hepatic transcatheter arterial chemoembolization complicated by postembolization syndrome. Semin Intervent Radiol. 2011;28:207-211. [PMID: 22654264 DOI: 10.1055/s-0031-1280666] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
33 Ricke J, Bulla K, Kolligs F, Peck-Radosavljevic M, Reimer P, Sangro B, Schott E, Schütte K, Verslype C, Walecki J. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. Liver Int. 2015;35:620-626. [PMID: 24930619 DOI: 10.1111/liv.12622] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 6.6] [Reference Citation Analysis]
34 Zhao Y, Cai G, Zhou L, Liu L, Qi X, Bai M, Li Y, Fan D, Han G. Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: A systematic review. Asia Pac J Clin Oncol. 2013;9:357-364. [PMID: 23714021 DOI: 10.1111/ajco.12081] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
35 Takayasu K. Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective. Jpn J Clin Oncol. 2012;42:247-255. [PMID: 22407946 DOI: 10.1093/jjco/hys020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
36 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol 2015; 7(5): 738-752 [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 5.1] [Reference Citation Analysis]
37 Liu W, Xu H, Ying X, Zhang D, Lai L, Wang L, Tu J, Ji J. Radiofrequency Ablation (RFA) Combined with Transcatheter Arterial Chemoembolization (TACE) for Patients with Medium-to-Large Hepatocellular Carcinoma: A Retrospective Analysis of Long-Term Outcome. Med Sci Monit 2020;26:e923263. [PMID: 32667906 DOI: 10.12659/MSM.923263] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
38 Steiner K, Papadopoulou A, Yu D. The role of interventional radiology in the treatment of hepatocellular carcinoma. Semin Ultrasound CT MR 2013;34:89-101. [PMID: 23395321 DOI: 10.1053/j.sult.2012.11.008] [Reference Citation Analysis]
39 Prajapati HJ, Kim HS. Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolization. PLoS One 2017;12:e0170750. [PMID: 28170405 DOI: 10.1371/journal.pone.0170750] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
40 Sanoff HK, Chang Y, Stavas JM, Stürmer T, Lund J. Effectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiaries. J Natl Compr Canc Netw 2015;13:1102-10. [PMID: 26358794 DOI: 10.6004/jnccn.2015.0135] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
41 Shuster A, Huynh TJ, Rajan DK, Marquez MA, Grant DR, Huynh DC, Jaskolka JD. Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Are Superior to European Association for Study of the Liver (EASL) Criteria at 1 Month Follow-up for Predicting Long-term Survival in Patients Treated with Transarterial Chemoembolization before Liver Transplantation for Hepatocellular Cancer. Journal of Vascular and Interventional Radiology 2013;24:805-12. [DOI: 10.1016/j.jvir.2013.01.499] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
42 Mahnken AH. Current status of transarterial radioembolization. World J Radiol 2016; 8(5): 449-459 [PMID: 27247711 DOI: 10.4329/wjr.v8.i5.449] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
43 Wang D, Gaba RC, Jin B, Riaz A, Lewandowski RJ, Ryu RK, Sato KT, Ragin AB, Kulik LM, Mulcahy MF, Salem R, Larson AC, Omary RA. Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinoma. Acad Radiol 2011;18:828-36. [PMID: 21669349 DOI: 10.1016/j.acra.2011.02.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
44 Bonekamp S, Li Z, Geschwind JF, Halappa VG, Corona-Villalobos CP, Reyes D, Pawlik TM, Bonekamp D, Eng J, Kamel IR. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria. Radiology 2013;268:420-30. [PMID: 23616631 DOI: 10.1148/radiol.13122307] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
45 Johnson PB, Cawich SO, Shah S, Gardner MT, Roberts P, Stedman B, Pearce NW. Vascular supply to the liver: a report of a rare arterial variant. Case Rep Radiol. 2013;2013:969327. [PMID: 24159405 DOI: 10.1155/2013/969327] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
46 Takayasu K. Transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: recent progression and perspective. Oncology. 2013;84 Suppl 1:28-33. [PMID: 23428855 DOI: 10.1159/000345886] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
47 Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, Sato KT, Marshall K, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Senthilnathan S, Baker T, Gates VL, Abecassis M, Benson AB 3rd, Mulcahy MF, Omary RA, Salem R. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011;141:526-35, 535.e1-2. [PMID: 21664356 DOI: 10.1053/j.gastro.2011.04.054] [Cited by in Crossref: 117] [Cited by in F6Publishing: 108] [Article Influence: 10.6] [Reference Citation Analysis]
48 Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB, Mulcahy MF. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497-507.e2. [PMID: 21044630 DOI: 10.1053/j.gastro.2010.10.049] [Cited by in Crossref: 390] [Cited by in F6Publishing: 366] [Article Influence: 32.5] [Reference Citation Analysis]
49 Wasan HS, Sangro B, Kennedy AS. Patient selection criteria for selective internal radiation therapy and integration into treatment guidelines. European Journal of Cancer Supplements 2012;10:76-80. [DOI: 10.1016/s1359-6349(12)70052-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
50 Xie F, Zang J, Guo X, Xu F, Shen R, Yan L, Yang J, He J. Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2012;138:455-62. [DOI: 10.1007/s00432-011-1117-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
51 Memon K, Lewandowski RJ, Riaz A, Salem R. Yttrium 90 microspheres for the treatment of hepatocellular carcinoma. Recent Results Cancer Res. 2013;190:207-224. [PMID: 22941023 DOI: 10.1007/978-3-642-16037-0_14] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
52 Salem R, Miller FH, Yaghmai V, Lewandowski RJ. Response assessment methodologies in hepatocellular carcinoma: Complexities in the era of local and systemic treatments. Journal of Hepatology 2013;58:1260-2. [DOI: 10.1016/j.jhep.2013.01.021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
53 Gaba RC, Vanmiddlesworth KA. Chemoembolic Hepatopulmonary Shunt Reduction to Allow Safe Yttrium-90 Radioembolization Lobectomy of Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2012;35:1505-11. [DOI: 10.1007/s00270-012-0371-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
54 Wang D, Gaba RC, Jin B, Lewandowski RJ, Riaz A, Memon K, Ryu RK, Sato KT, Kulik LM, Mulcahy MF, Larson AC, Salem R, Omary RA. Perfusion reduction at transcatheter intraarterial perfusion MR imaging: a promising intraprocedural biomarker to predict transplant-free survival during chemoembolization of hepatocellular carcinoma. Radiology 2014;272:587-97. [PMID: 24678859 DOI: 10.1148/radiol.14131311] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
55 Weintraub JL, Salem R. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science. J Vasc Interv Radiol. 2013;24:1123-1134. [PMID: 23562168 DOI: 10.1016/j.jvir.2013.01.494] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
56 He X, Guo X, Zhang H, Kong X, Yang F, Zheng C. Mechanism of action and efficacy of LY2109761, a TGF-β receptor inhibitor, targeting tumor microenvironment in liver cancer after TACE. Oncotarget 2018;9:1130-42. [PMID: 29416682 DOI: 10.18632/oncotarget.23193] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
57 Sellers MT, Huggins S, Kegley K, Pollinger HS, Shrestha R, Johnson MW, Stein LL, Panjala C, Tan M, Arepally A. Multivariate analysis of prognostic factors for survival following doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2013;24:647-654. [PMID: 23384831 DOI: 10.1016/j.jvir.2012.12.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
58 Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, Mulcahy MF, Baker T, Abecassis M, Miller FH, Yaghmai V, Sato K, Desai K, Thornburg B, Benson AB, Rademaker A, Ganger D, Kulik L, Lewandowski RJ. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;151:1155-1163.e2. [PMID: 27575820 DOI: 10.1053/j.gastro.2016.08.029] [Cited by in Crossref: 243] [Cited by in F6Publishing: 209] [Article Influence: 40.5] [Reference Citation Analysis]
59 Rostambeigi N, Dekarske AS, Austin EE, Golzarian J, Cressman EN. Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Vasc Interv Radiol. 2014;25:1075-1084. [PMID: 24861664 DOI: 10.1016/j.jvir.2014.04.014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
60 Sandow TA, Arndt SE, Albar AA, DeVun DA, Kirsch DS, Gimenez JM, Bohorquez HE, Gilbert PJ, Thevenot PT, Nunez KG, Galliano GA, Cohen AJ, Kay D, Gulotta PM. Assessment of Response to Transcatheter Arterial Chemoembolization with Doxorubicin-eluting Microspheres: Tumor Biology and Hepatocellular Carcinoma Recurrence in a 5-year Transplant Cohort. Radiology 2018;286:1072-83. [PMID: 29206595 DOI: 10.1148/radiol.2017170731] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
61 Chen BB, Shih IL, Wu CH, Hsu C, Chen CH, Shih TT, Liu KL, Liang PC. Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies. J Vasc Interv Radiol. 2014;25:371-378. [PMID: 24468045 DOI: 10.1016/j.jvir.2013.10.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
62 Taslakian B, Sridhar D. Post-procedural Care in Interventional Radiology: What Every Interventional Radiologist Should Know-Part II: Catheter Care and Management of Common Systemic Post-procedural Complications. Cardiovasc Intervent Radiol 2017;40:1304-20. [PMID: 28584946 DOI: 10.1007/s00270-017-1709-y] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
63 Zhang B, Guo Y, Wu K, Shan H. Intrahepatic biloma following transcatheter arterial chemoembolization for hepatocellular carcinoma: Incidence, imaging features and management. Mol Clin Oncol 2017;6:937-43. [PMID: 28588794 DOI: 10.3892/mco.2017.1235] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
64 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol. 2015;7:738-752. [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Somma F, Stoia V, Serra N, D'Angelo R, Gatta G, Fiore F. Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival. PLoS One 2019;14:e0216935. [PMID: 31141552 DOI: 10.1371/journal.pone.0216935] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
66 Tu J, Ji J, Wu F, Wang Y, Zhang D, Zhao Z, Ying X. Effectiveness of combined (131)I-chTNT and radiofrequency ablation therapy in treating advanced hepatocellular carcinoma. Cell Biochem Biophys. 2015;71:777-784. [PMID: 25293788 DOI: 10.1007/s12013-014-0262-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
67 Kim AY, Frantz S, Krishnan P, DeMulder D, Caridi T, Lynskey GE, Spies JB. Short-term imaging response after drug-eluting embolic trans-arterial chemoembolization delivered with the Surefire Infusion System® for the treatment of hepatocellular carcinoma. PLoS One 2017;12:e0183861. [PMID: 28863147 DOI: 10.1371/journal.pone.0183861] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
68 Cappelli A, Pettinato C, Golfieri R. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. J Hepatocell Carcinoma 2014;1:163-82. [PMID: 27508185 DOI: 10.2147/JHC.S50472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
69 Yang ZW, He W, Zheng Y, Zou RH, Liu WW, Zhang YP, Wang CW, Wang YJ, Yuan YC, Li BK, Yuan YF. The efficacy and safety of long- versus short-interval transarterial chemoembolization in unresectable hepatocellular carcinoma. J Cancer 2018;9:4000-8. [PMID: 30410605 DOI: 10.7150/jca.24250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
70 Georgiades C, Geschwind JF, Harrison N, Hines-Peralta A, Liapi E, Hong K, Wu Z, Kamel I, Frangakis C. Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology 2012;265:115-23. [PMID: 22891361 DOI: 10.1148/radiol.12112264] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 7.2] [Reference Citation Analysis]
71 Favelier S, Boulin M, Hamza S, Cercueil J, Cherblanc V, Lepage C, Hillon P, Chauffert B, Krausé D, Guiu B. Lipiodol Trans-arterial Chemoembolization of Hepatocellular Carcinoma with Idarubicin: First Experience. Cardiovasc Intervent Radiol 2013;36:1039-46. [DOI: 10.1007/s00270-012-0532-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
72 Seinstra BA, Defreyne L, Lambert B, Lam MG, Verkooijen HM, van Erpecum KJ, van Hoek B, van Erkel AR, Coenraad MJ, Al Younis I. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. Trials. 2012;13:144. [PMID: 22913492 DOI: 10.1186/1745-6215-13-144] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
73 Memon K, Kulik L, Lewandowski RJ, Gupta R, Ryu RK, Miller FH, Vouche M, Atassi R, Ganger D, Mulcahy MF, Salem R. Prospective Evaluation of Patients with Early-/Intermediate-stage Hepatocellular Carcinoma with Disease Progression Following Arterial Locoregional Therapy: Candidacy for Systemic Treatment or Clinical Trials. Journal of Vascular and Interventional Radiology 2013;24:1189-1197.e2. [DOI: 10.1016/j.jvir.2012.12.025] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
74 Lionço LC, de Mattos AA, Horbe AF, Costabeber AM, de Mattos ÂZ, Tarasconi DP. Treatment of hepatocellular carcinoma using transarterial chemoembolization: a real-life, single-centre study from Southern Brazil. Eur J Gastroenterol Hepatol 2017;29:225-30. [PMID: 27759574 DOI: 10.1097/MEG.0000000000000764] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
75 Gaba RC, Brodsky TR, Knuttinen MG, Omene BO, Owens CA, Bui JT. Hepatic arterial changes following iodized oil chemoembolization of hepatocellular carcinoma: Incidence and technical consequence. ARTRES 2012;6:21. [DOI: 10.1016/j.artres.2011.08.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
76 Choi J, Shim JH, Shin YM, Kim KM, Lim YS, Lee HC. Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma. J Hepatol. 2014;60:1212-1218. [PMID: 24486088 DOI: 10.1016/j.jhep.2014.01.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
77 Tanaka Y, Hashimoto T, Watanabe D, Okada H, Kato D, Aoyagi S, Akimoto J, Kohno M. Post-embolization neurological syndrome after embolization for intracranial and skull base tumors: transient exacerbation of neurological symptoms with inflammatory responses. Neuroradiology 2018;60:843-51. [DOI: 10.1007/s00234-018-2047-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
78 Wang ZX, Li L, Tao FY. Health education helps to relieve postembolization pain during hepatic arterial chemoembolization therapy. J Pain Res 2018;11:2115-21. [PMID: 30319286 DOI: 10.2147/JPR.S166333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Seyal AR, Gonzalez-Guindalini FD, Arslanoglu A, Harmath CB, Lewandowski RJ, Salem R, Yaghmai V. Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma. Hepatology. 2015;62:1111-1121. [PMID: 25999236 DOI: 10.1002/hep.27915] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
80 Roberts SK, Gazzola A, Lubel J, Gow P, Bell S, Nicoll A, Dev A, Fink MA, Sood S, Knight V, Hong T, Paul E, Mishra G, Majeed A, Kemp W; Melbourne Liver Group. Treatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival. Scand J Gastroenterol 2018;53:1368-75. [PMID: 30394145 DOI: 10.1080/00365521.2018.1517277] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
81 Casadaban LC, Minocha J, Bui JT, Knuttinen MG, Ray CE, Gaba RC. Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes. American Journal of Roentgenology 2016;206:645-54. [DOI: 10.2214/ajr.15.14758] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
82 Senthilnathan S, Memon K, Lewandowski RJ, Kulik L, Mulcahy MF, Riaz A, Miller FH, Yaghmai V, Nikolaidis P, Wang E. Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: analyzing patterns of progression in 285 patients. Hepatology. 2012;55:1432-1442. [PMID: 22109811 DOI: 10.1002/hep.24812] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 4.6] [Reference Citation Analysis]
83 Gaba RC, Yap FY, Martinez EM, Li Y, Guzman G, Parvinian A, van Breemen RB, Kumar N. Transarterial sorafenib chemoembolization: preliminary study of technical feasibility in a rabbit model. J Vasc Interv Radiol 2013;24:744-50. [PMID: 23510657 DOI: 10.1016/j.jvir.2013.01.488] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
84 Yasaka K, Gonoi W, Akai H, Katsura M, Akahane M, Kiryu S, Ohtomo K. Differentiation of adrenal tumors in patients with hepatocellular carcinoma: adrenal adenoma versus metastasis. Eur J Radiol 2013;82:1213-8. [PMID: 23478006 DOI: 10.1016/j.ejrad.2013.02.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
85 Fowler KJ, Maughan NM, Laforest R, Saad NE, Sharma A, Olsen J, Speirs CK, Parikh PJ. PET/MRI of Hepatic 90Y Microsphere Deposition Determines Individual Tumor Response. Cardiovasc Intervent Radiol. 2015;Epub ahead of print. [PMID: 26721589 DOI: 10.1007/s00270-015-1285-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
86 Rimola J, Davenport MS, Liu PS, Brown T, Marrero JA, Mckenna BJ, Hussain HK. Diagnostic accuracy of MRI with extracellular vs. hepatobiliary contrast material for detection of residual hepatocellular carcinoma after locoregional treatment. Abdom Radiol 2019;44:549-58. [DOI: 10.1007/s00261-018-1775-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
87 Yu SCH, Chan SL, Lee KF, Hui JWY, Hui EP, Chu CM, Chan AW, Cheung S, Li L, Wong J, Yeo WMM. Ablative Chemoembolization for Hepatocellular Carcinoma: A Prospective Phase I Case-Control Comparison with Conventional Chemoembolization. Radiology 2018;287:340-8. [DOI: 10.1148/radiol.2017170154] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
88 Chapiro J, Tacher V, Geschwind JF. Intraarterial therapies for primary liver cancer: state of the art. Expert Rev Anticancer Ther 2013;13:1157-67. [PMID: 24099626 DOI: 10.1586/14737140.2013.845528] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
89 Memon K, Lewandowski RJ, Riaz A, Salem R. Chemoembolization and Radioembolization for Metastatic Disease to the Liver: Available Data and Future Studies. Curr Treat Options in Oncol 2012;13:403-15. [DOI: 10.1007/s11864-012-0200-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
90 Iñarrairaegui M, Pardo F, Bilbao J, Rotellar F, Benito A, D'avola D, Herrero J, Rodriguez M, Martí P, Zozaya G, Dominguez I, Quiroga J, Sangro B. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. European Journal of Surgical Oncology (EJSO) 2012;38:594-601. [DOI: 10.1016/j.ejso.2012.02.189] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 7.0] [Reference Citation Analysis]
91 Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R. Locoregional Therapy of Hepatocellular Carcinoma. Clinics in Liver Disease 2015;19:401-20. [DOI: 10.1016/j.cld.2015.01.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
92 Golfieri R, Renzulli M, Mosconi C, Forlani L, Giampalma E, Piscaglia F, Trevisani F, Bolondi L. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? J Vasc Interv Radiol. 2013;24:509-517. [PMID: 23428355 DOI: 10.1016/j.jvir.2012.12.013] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 6.1] [Reference Citation Analysis]
93 Wu B, Zhou J, Ling G, Zhu D, Long Q. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study. World J Surg Oncol. 2018;16:69. [PMID: 29587773 DOI: 10.1186/s12957-018-1368-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
94 Hickey R, Mouli S, Kulik L, Desai K, Thornburg B, Ganger D, Baker T, Abecassis M, Ralph Kallini J, Gabr A, Gates VL, Benson Iii AB, Lewandowski RJ, Salem R. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma. J Vasc Interv Radiol. 2016;27:795-802. [PMID: 27038686 DOI: 10.1016/j.jvir.2016.03.005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
95 Mason MC, Massarweh NN, Salami A, Sultenfuss MA, Anaya DA. Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma. HPB (Oxford) 2015;17:1137-44. [PMID: 26374137 DOI: 10.1111/hpb.12487] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
96 Marin D, Cappabianca S, Serra N, Sica A, Lassandro F, D'Angelo R, La Porta M, Fiore F, Somma F. CT Appearance of Hepatocellular Carcinoma after Locoregional Treatments: A Comprehensive Review. Gastroenterol Res Pract 2015;2015:670965. [PMID: 26798332 DOI: 10.1155/2015/670965] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
97 Liu YS, Ou MC, Tsai YS, Lin XZ, Wang CK, Tsai HM, Chuang MT. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma. Korean J Radiol. 2015;16:125-132. [PMID: 25598680 DOI: 10.3348/kjr.2015.16.1.125] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
98 Shaw CM, Eisenbrey JR, Lyshchik A, O'kane PL, Merton DA, Machado P, Pino L, Brown DB, Forsberg F. Contrast-Enhanced Ultrasound Evaluation of Residual Blood Flow to Hepatocellular Carcinoma After Treatment With Transarterial Chemoembolization Using Drug-Eluting Beads: A Prospective Study. Journal of Ultrasound in Medicine 2015;34:859-67. [DOI: 10.7863/ultra.34.5.859] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
99 Pinato DJ, Howell J, Ramaswami R, Sharma R. Review article: delivering precision oncology in intermediate-stage liver cancer. Aliment Pharmacol Ther 2017;45:1514-23. [DOI: 10.1111/apt.14066] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
100 Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, Baker T, Abecassis MM, Atassi R, Riaz A, Cella D, Burns JL, Ganger D, Benson AB, Mulcahy MF, Kulik L, Lewandowski R. Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated With Radioembolization, Compared With Chemoembolization. Clinical Gastroenterology and Hepatology 2013;11:1358-1365.e1. [DOI: 10.1016/j.cgh.2013.04.028] [Cited by in Crossref: 127] [Cited by in F6Publishing: 117] [Article Influence: 14.1] [Reference Citation Analysis]
101 Ramanathan M, Seetharam A. Intra-arterial locoregional therapy in the management of hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2018;11:6-10. [PMID: 30992780 DOI: 10.1002/cld.682] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
102 Wan YM, Li YH, Xu ZY, Wu HM, Xu Y, Yang M, Wu XN. The Effect of Transarterial Chemoembolization in Combination With Kang'ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study. Integr Cancer Ther 2018;17:477-85. [PMID: 29108428 DOI: 10.1177/1534735417734913] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
103 Memon K, Kulik L, Lewandowski RJ, Wang E, Ryu RK, Riaz A, Nikolaidis P, Miller FH, Yaghmai V, Baker T, Abecassis M, Benson AB, Mulcahy MF, Omary RA, Salem R. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J Hepatol. 2012;56:1112-1120. [PMID: 22245905 DOI: 10.1016/j.jhep.2011.11.020] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 6.1] [Reference Citation Analysis]
104 Best J, Schotten C, Theysohn JM, Wetter A, Müller S, Radünz S, Schulze M, Canbay A, Dechêne A, Gerken G. Novel implications in the treatment of hepatocellular carcinoma. Ann Gastroenterol 2017;30:23-32. [PMID: 28042235 DOI: 10.20524/aog.2016.0092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 16] [Article Influence: 0.5] [Reference Citation Analysis]
105 Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology 2011;259:641-57. [PMID: 21602502 DOI: 10.1148/radiol.11081489] [Cited by in Crossref: 140] [Cited by in F6Publishing: 132] [Article Influence: 12.7] [Reference Citation Analysis]
106 Zeeneldin AA, Salem SE, Tabashy RH, Ibrahim AA, Alieldin NH. Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a single center experience including 221 patients. J Egypt Natl Canc Inst 2013;25:143-50. [PMID: 23932751 DOI: 10.1016/j.jnci.2013.05.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
107 Agarwal A, Yadav AK, Kumar A, Gupta S, Panwala HK, Redhu N, Hariprasad S, Ranjan P, Arora A, Gupta A. Transarterial chemoembolization in unresectable hepatocellular carcinoma--assessing the factors affecting the survival: An audit from a tertiary care center in northern India. Indian J Gastroenterol 2015;34:117-26. [PMID: 25937484 DOI: 10.1007/s12664-015-0544-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]